Walleye Capital
SLXNW

Walleye Capital’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Walleye Capital’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,000
Closed -$666 – 5723
2024
Q3 		$666 Buy
+21,000
New +$1.22K ﹤0.01% 5159

Other funds holding SLXNW

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Walleye Capital's SLXNW Position: Q4 2024 in Review

Walleye Capital sold out of Silexion Therapeutics Warrant (SLXNW) in Q4 2024, closing a stake of 21,000 shares — an estimated $666 sold.

Walleye Capital first reported a position in SLXNW in Q3 2024 and held it in 1 quarter. The position peaked at $666 in Q3 2024. 26 funds tracked by Wall St. Rank hold SLXNW as of Q4 2024.

  • Walleye Capital reported no remaining Silexion Therapeutics Warrant position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 21,000 Silexion Therapeutics Warrant shares in Q4 2024, an estimated $666.
  • Walleye Capital first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 1 quarter.
  • Walleye Capital's Silexion Therapeutics Warrant position peaked at $666 in Q3 2024.
  • 26 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.